STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences, Inc. - GILD STOCK NEWS

Welcome to our dedicated news page for Gilead Sciences (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.

News
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Rhea-AI Summary
Gilead Sciences and Merck announce positive Phase 2 clinical study results for a potential long-acting oral combination treatment for people with HIV. The investigational combination of islatravir and lenacapavir maintained a high rate of viral suppression at 24 weeks, supporting its development as a once-weekly oral regimen. This novel treatment option aims to address adherence and stigma challenges faced by individuals with HIV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
clinical trial
-
News
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Rhea-AI Summary
Gilead Sciences and Merus N.V. collaborate to develop novel trispecific antibodies targeting dual tumor-associated antigens. Merus to lead early-stage research with Gilead having the option to license resulting programs. The agreement includes upfront payments, equity investment, and potential milestone payments totaling up to $1.5 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
News
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
Rhea-AI Summary
Gilead Sciences, Inc. (GILD) announces positive real-world data on Veklury (remdesivir) at CROI, showing reduced risk of long-COVID symptoms and mortality among hospitalized COVID-19 patients, including the immunocompromised.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
covid-19
News
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
Rhea-AI Summary
Gilead Sciences presents positive clinical data on innovative HIV treatment research pipeline at CROI. The data includes studies on investigational combination regimens, long-acting dosing strategies, and once-weekly integrase strand transfer inhibitor. Results show potential for transforming HIV management and addressing unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
News
Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area
Rhea-AI Summary
Gilead Sciences, under the leadership of CEO Daniel O'Day, has seen significant growth and expansion in antiviral and cancer therapies. With a strong economic impact of $22.1 billion in 2020, the company boasts a diverse pipeline of new medicines across various diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
-
News
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Rhea-AI Summary
RedHill Biopharma's opaganib selected by U.S. government for evaluation as a medical countermeasure against Sulfur Mustard exposure. Opaganib, a novel oral small molecule, shows promise for multiple indications including COVID-19 and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
News
Gilead Sciences: National Black HIV/AIDS Awareness Day
Rhea-AI Summary
National Black HIV/AIDS Awareness Day 2024 focuses on 'Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities'. C. Virginia Fields from National Black Leadership Commission on Health discusses Gilead's involvement as a grantee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
-
News
Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
Rhea-AI Summary
Gilead Sciences, Inc. is providing $12.6 million in grant funding to 19 organizations through its Setting the P.A.C.E. Initiative to improve the HIV landscape for Black women and girls in the U.S. This initiative aims to increase HIV prevention efforts and health equity for Black cisgender and Transgender women and girls who are disproportionately affected by the HIV epidemic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
-
News
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
Rhea-AI Summary
Gilead Sciences, Inc. announces $12.6 million grant funding for 19 organizations to improve HIV landscape for Black women and girls in the U.S. as part of Setting the P.A.C.E. initiative. The grants aim to increase HIV prevention, anti-stigma efforts, and health equity for Black cisgender and Transgender women and girls disproportionately impacted by the HIV epidemic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
News
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
Rhea-AI Summary
Gilead Sciences, Inc. announces FDA approval for Biktarvy to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Biktarvy is now the first and only INSTI-based single-tablet regimen approved for this specific group, providing a high barrier to resistance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
fda approval
Stock GILD logo
Gilead Sciences, Inc.

Nasdaq:GILD

GILD Rankings

#136 Ranked by Market Cap
#2131 Ranked by Stock Gains
#728 Ranked by Dividends

GILD Stock Data

84.88B
1.24B
0.09%
88.37%
1.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Foster City

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.